Revenio Group Oyj (HEL:REG1V)

Market Cap	487.37M -29.9%
Revenue (ttm)	109.90M +5.9%
Net Income	17.40M -5.9%
EPS	0.66 -5.8%
Shares Out	26.60M
PE Ratio	27.97
Forward PE	22.02
Dividend	0.44 (2.41%)
Ex-Dividend Date	Apr 16, 2026

Volume	34,305
Average Volume	46,460
Open	18.24
Previous Close	18.24
Day's Range	18.24 - 18.54
52-Week Range	17.36 - 29.80
Beta	1.22
RSI	51.66
Earnings Date	Apr 28, 2026

About Revenio Group Oyj

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for mea...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 247
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: REG1V

Financial Performance

In 2025, Revenio Group Oyj's revenue was 109.90 million, an increase of 5.86% compared to the previous year's 103.82 million. Earnings were 17.40 million, a decrease of -5.93%.